{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:59:03Z","timestamp":1790697543647,"version":"4.1.0"},"reference-count":107,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Prevention of the consequences of atherosclerotic disease has traditionally focused on controlling individual risk factors such as dyslipidaemia, hypertension and diabetes. In recent years, the term residual risk has been used to describe the persistence of cardiovascular events despite the optimal management of these classical risk factors, with particular attention given to inflammation. Far less attention, however, has been paid to environmental risk factors, which affect entire populations and may account for a substantial proportion of temporal variations in event incidence, as well as the marked seasonal fluctuations in hospital admissions for cardiovascular disease that periodically place considerable pressure on healthcare systems. Temperature, air pollution and infectious diseases\u2014particularly respiratory infections\u2014may help explain why an individual with a given baseline risk experiences an event in one month rather than another. Some environmental factors may promote the development of classical risk factors, whereas others may contribute directly to atherosclerosis. All of them may act either as triggers for acute ischemic events or as destabilising factors in previously stable patients, for example those with heart failure. Infections, especially those of respiratory tract, play a key role in the natural history of cardiovascular disease. Growing evidence indicates that preventing infections through vaccination can reduce the risk of acute ischemic events, hospitalisation and death. Nevertheless, vaccination coverage for many infections, including influenza and Coronavirus disease 2019 (COVID-19), remains low. In addition, pseudo-scientific campaigns continue to spread misinformation about vaccines, thereby reducing patient adherence. Leading cardiology societies now recognise vaccination against certain infections as an evidence-based strategy for cardiovascular prevention. It is therefore essential that this information be widely disseminated among healthcare professionals, patients and the general public. Of all the available measures to control environmental risk factors, vaccination is the only intervention that clinicians can directly implement in routine clinical practice. Vaccination recommendations should therefore be regarded with the same importance as advice on diet, exercise and smoking cessation.<\/jats:p>","DOI":"10.31083\/rcm54010","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:11Z","timestamp":1790693831000},"source":"Crossref","is-referenced-by-count":0,"title":["Vaccination as a Strategy for Cardiovascular Prevention: Closing a Gap in Clinical Practice"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4709-9732","authenticated-orcid":true,"given":"Elvira","family":"Garc\u00eda-de-Santiago","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Universidad de Alcal\u00e1, 28805 Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2584","authenticated-orcid":true,"given":"Alberto","family":"Garc\u00eda-Lled\u00f3","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidad de Alcal\u00e1, 28805 Alcal\u00e1 de Henares, Madrid, Spain"},{"name":"Department of Cardiology, University Hospital Pr\u00edncipe de Asturias, 28805 Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet (London, England). 2025; 406: 1811\u20131872.","DOI":"10.1016\/S0140-6736(25)01917-8"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"D\u00edaz-Polanco JC, Tejada-Gonz\u00e1lez C, Leandro-Barros A, Ruiz-Saavedra A, Garc\u00eda-de-Santiago E, Alonso-Mart\u00edn J, et al. Seasonal Stability of the Circadian Rhythm in Patients with Type I Myocardial Infarction. Reviews in Cardiovascular Medicine. 2024; 25: 259.","DOI":"10.31083\/j.rcm2507259"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Fowler T, Southgate RJ, Waite T, Harrell R, Kovats S, Bone A, et al. Excess winter deaths in Europe: a multi-country descriptive analysis. European Journal of Public Health. 2015; 25: 339\u2013345.","DOI":"10.1093\/eurpub\/cku073"},{"key":"ref4","unstructured":"Carlos III Health Institute. MoMo: Daily Mortality Monitoring System. Madrid: ISCIII. Available at: https:\/\/momo.isciii.es\/panel_momo\/ (Accessed: 15 May 2026). (In Spanish)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Lled\u00f3 A, Rodr\u00edguez-Mart\u00edn S, Tob\u00edas A, Garc\u00eda-de-Santiago E, Ordob\u00e1s-Gav\u00edn M, Ansede-Cascudo JC, et al. Relationship Between Influenza, Temperature, and Type 1 Myocardial Infarction: An Ecological Time-Series Study. Journal of the American Heart Association. 2021; 10: e019608.","DOI":"10.1161\/JAHA.120.019608"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gong XY, Dong ZC, Sha TT, Li Q, Dou YJ, Zhang HX, et al. Interactive effects of diurnal temperature range and air pollution on myocardial infarction incidence: an individual-level case-crossover study. Scientific Reports. 2026; 16: 10688.","DOI":"10.1038\/s41598-026-46261-y"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-de-Santiago E, Lozano-Batuecas M, Garc\u00eda-P\u00e9rez-Velasco J, G\u00f3mez-Delgado J, Garc\u00eda-Arribas D, Herruzo-Le\u00f3n A, et al. Wealth, Unemployment, Social Investment, and Risk of ST-Segment Elevation Myocardial Infarction-An Ecological Analysis of a Low-Cardiovascular-Risk European Region. Journal of Clinical Medicine. 2025; 14: 7707.","DOI":"10.3390\/jcm14217707"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bergen N, Kirkby K, Fuertes CV, Schlotheuber A, Menning L, Mac Feely S, et al. Global state of education-related inequality in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine refusal: findings from the Global COVID-19 Trends and Impact Survey. The Lancet. Global Health. 2023; 11: e207\u2013e217.","DOI":"10.1016\/S2214-109X(22)00520-4"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hanneman K, Alahmad B, Ghosh A, Khatana SAM, Huang M, Liu J, et al. Nonoptimal Temperature and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2026; 153: e1130\u2013e1150.","DOI":"10.1161\/CIR.0000000000001419"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. The New England Journal of Medicine. 2004; 351: 2611\u20132618.","DOI":"10.1056\/NEJMoa041747"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Pedersen EMJ, Yonis H, Egelund GB, Lohse N, Torp-Pedersen C, Lindegaard B, et al. Severe infections as risk factors for acute myocardial infarction: a nationwide, Danish cohort study from 1987 to 2018. European Journal of Preventive Cardiology. 2025; 32: 661\u2013670.","DOI":"10.1093\/eurjpc\/zwae344"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Corrales-Medina VF, Fatemi O, Serpa J, Valayam J, Bozkurt B, Madjid M, et al. The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scandinavian Journal of Infectious Diseases. 2009; 41: 511\u2013514.","DOI":"10.1080\/00365540902913460"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Kawai K, Muhere CF, Lemos EV, Francis JM. Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2025; 14: e042670.","DOI":"10.1161\/JAHA.125.042670"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Wee LE, Lim JT, Ho RWL, Chiew CJ, Lye DCB, Tan KB. Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza. JAMA Network Open. 2025; 8: e2511764.","DOI":"10.1001\/jamanetworkopen.2025.11764"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CCH, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015; 313: 264\u2013274.","DOI":"10.1001\/jama.2014.18229"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. The New England Journal of Medicine. 2018; 378: 345\u2013353.","DOI":"10.1056\/NEJMoa1702090"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. The European Respiratory Journal. 2018; 51: 1701794.","DOI":"10.1183\/13993003.01794-2017"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. International Journal of Cardiology. 2023; 372: 138\u2013143.","DOI":"10.1016\/j.ijcard.2022.12.032"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Warren-Gash C, Davidson JA, Strongman H, Herrett E, Smeeth L, Breuer J, et al. Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020: a population-based cohort study. The Lancet Regional Health. Europe. 2023; 27: 100604.","DOI":"10.1016\/j.lanepe.2023.100604"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kaklikkaya I, Kaklikkaya N, Birincioglu I, Buruk K, Turan N. Detection of human herpesvirus 6 DNA but not human herpesvirus 7 or 8 DNA in atherosclerotic and nonatherosclerotic vascular tissues. The Heart Surgery Forum. 2010; 13: E345\u2013E349.","DOI":"10.1532\/HSF98.20101023"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"\u0160a\u010di\u0107 D, Tomi\u0107 U, Mila\u0161in J, Putnik S, Jovanovi\u0107 M, Radojevi\u0107 \u0160kodri\u0107 S, et al. The Detection of Chlamydia pneumoniae, Helicobacter pylori and Cytomegalovirus in Non-Atherosclerotic Arteries of Patients with Coronary Artery Disease. Pathogens (Basel, Switzerland). 2024; 13: 927.","DOI":"10.3390\/pathogens13110927"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Hetta HF, Alanazi FE, Alshareef H, Alqifari SF, Bukhari SQ, Albalwi MA, et al. Antiviral Drugs in HIV and Cardiovascular Disease: Mechanistic Insights and Clinical Implications. Pharmaceuticals (Basel, Switzerland). 2026; 19: 205.","DOI":"10.3390\/ph19020205"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zheng J, Yang Q, Huang J, Chen H, Shen J, Tang S. Hospital-treated infectious diseases, genetic susceptibility and risk of type 2 diabetes: A population-based longitudinal study. Diabetes & Metabolic Syndrome. 2024; 18: 103063.","DOI":"10.1016\/j.dsx.2024.103063"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Bomfim GF, Priviero F, Poole E, Tostes RC, Sinclair JH, Stamou D, et al. Cytomegalovirus and Cardiovascular Disease: A Hypothetical Role for Viral G-Protein-Coupled Receptors in Hypertension. American Journal of Hypertension. 2023; 36: 471\u2013480.","DOI":"10.1093\/ajh\/hpad045"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Gaonkar A, Zahiruddin QS, Shabil M, Menon SV, Kaur M, Kumari M, et al. Association of Helicobacter pylori Infection and Risk of Dyslipidemia: A Systematic Review and Meta-Analysis. JGH Open: an Open Access Journal of Gastroenterology and Hepatology. 2025; 9: e70128.","DOI":"10.1002\/jgh3.70128"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019; 40: 237\u2013269.","DOI":"10.1093\/eurheartj\/ehy462"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023; 44: 3720\u20133826.","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Roston TM, Aghanya V, Savu A, Fordyce CB, Lawler PR, Jentzer J, et al. Premature Acute Myocardial Infarction Treated With Invasive Revascularization: Comparing STEMI With NSTEMI in a Population-Based Study of Young Patients. The Canadian Journal of Cardiology. 2024; 40: 2079\u20132088.","DOI":"10.1016\/j.cjca.2024.07.001"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Vejpongsa P, Kitkungvan D, Madjid M, Charitakis K, Anderson HV, Arain S, et al. Outcomes of Acute Myocardial Infarction in Patients with Influenza and Other Viral Respiratory Infections. The American Journal of Medicine. 2019; 132: 1173\u20131181.","DOI":"10.1016\/j.amjmed.2019.05.002"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Harris JE, Shah PJ, Korimilli V, Win H. Frequency of troponin elevations in patients with influenza infection during the 2017-2018 influenza season. International Journal of Cardiology. 2019; 22: 145\u2013147.","DOI":"10.1016\/j.ijcha.2018.12.013"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Hayase N, Yamamoto M, Asada T, Isshiki R, Doi K. Tachycardia and Acute Kidney Injury among Critically Ill Patients with Sepsis: A Prospective Observational Study. Blood Purification. 2024; 53: 641\u2013649.","DOI":"10.1159\/000539808"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovascular Research. 2021; 117: 2525\u20132536.","DOI":"10.1093\/cvr\/cvab303"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994; 89: 36\u201344.","DOI":"10.1161\/01.cir.89.1.36"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nature Reviews. Cardiology. 2021; 18: 666\u2013682.","DOI":"10.1038\/s41569-021-00552-1"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"de Boer AR, Riezebos-Brilman A, van Hout D, van Mourik MSM, R\u00fcmke LW, de Hoog MLA, et al. Influenza Infection and Acute Myocardial Infarction. NEJM Evidence. 2024; 3: EVIDoa2300361.","DOI":"10.1056\/EVIDoa2300361"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. The Journal of Infectious Diseases. 2012; 206: 1652\u20131659.","DOI":"10.1093\/infdis\/jis597"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Carneiro J, Leite A, Lahuerta M, Catusse J, Ali M, Teixeira R, et al. Risk of stroke or myocardial infarction hospitalisation following hospitalisation for community-acquired pneumonia in Portugal: a self-controlled case series study. BMJ Open. 2025; 15: e101068.","DOI":"10.1136\/bmjopen-2025-101068"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, Madjid M, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine. 2009; 88: 154\u2013159.","DOI":"10.1097\/MD.0b013e3181a692f0"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2007; 45: 158\u2013165.","DOI":"10.1086\/518849"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Ohland J, Warren-Gash C, Blackburn R, M\u00f8lbak K, Valentiner-Branth P, Nielsen J, et al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark, 2010 to 2016. European Communicable Disease Bulletin. 2020; 25: 1900199.","DOI":"10.2807\/1560-7917.ES.2020.25.17.1900199"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Penders Y, Falsey AR, Bhatt DL, B\u00f6hm M, Coats AJS, Mason LMK, et al. Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: A systematic literature review. Progress in Cardiovascular Diseases. 2025; 92: 130\u2013143.","DOI":"10.1016\/j.pcad.2025.06.010"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Verschoor CP, Cerasuolo JO, Caswell JM, Tatangelo M, Costa-Vitali A, Savage DW, et al. Respiratory Syncytial Virus (RSV)-Related Hospitalization and Increased Rate of Cardiovascular Events in Older Adults. Journal of the American Geriatrics Society. 2025; 73: 2685\u20132694.","DOI":"10.1111\/jgs.19591"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Internal Medicine. 2024; 184: 602\u2013611.","DOI":"10.1001\/jamainternmed.2024.0212"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga MEDS, et al. Vaccines for preventing herpes zoster in older adults. The Cochrane Database of Systematic Reviews. 2023; 10: CD008858.","DOI":"10.1002\/14651858.CD008858.pub5"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Parameswaran GI, Drye AF, Wattengel BA, Carter MT, Doyle KM, Mergenhagen KA. Increased Myocardial Infarction Risk Following Herpes Zoster Infection. Open Forum Infectious Diseases. 2023; 10: ofad137.","DOI":"10.1093\/ofid\/ofad137"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zhang Y, Luo G, Huang Y, Yu Q, Wang L, Li K. Risk of Stroke\/Transient Ischemic Attack or Myocardial Infarction with Herpes Zoster: A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association. 2017; 26: 1807\u20131816.","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.013"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Lai HY, Meng LC, Chen HM, Chuang HM, Chen LK, Hsiao FY. Herpes zoster infection and myocardial infarction risk: Evaluating the impact of antiviral therapy in a nationwide self-controlled case series study. Journal of Infection and Public Health. 2026; 19: 103008.","DOI":"10.1016\/j.jiph.2025.103008"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Salata C, Calistri A, Parolin C, Pal\u00f9 G. Coronaviruses: a paradigm of new emerging zoonotic diseases. Pathogens and Disease. 2019; 77: ftaa006.","DOI":"10.1093\/femspd\/ftaa006"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet (London, England). 2022; 399: 1513\u20131536.","DOI":"10.1016\/S0140-6736(21)02796-3"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Romero Starke K, Kaboth P, Rath N, Reissig D, Kaempf D, Nienhaus A, et al. Cardiovascular disease risk after a SARS-CoV-2 infection: A systematic review and meta-analysis. The Journal of Infection. 2024; 89: 106215.","DOI":"10.1016\/j.jinf.2024.106215"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Katsoularis I, Fonseca-Rodr\u00edguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet (London, England). 2021; 398: 599\u2013607.","DOI":"10.1016\/S0140-6736(21)00896-5"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: Past, present, and future. Reviews in Medical Virology. 2022; 32: e2243.","DOI":"10.1002\/rmv.2243"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Hsu D, Jayaraman A, Pucci A, Joshi R, Mancini K, Chen HL, et al. Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A\/H3N2 strains with or without the B\/Yamagata strain in US adults aged 50-75 years: a phase 1\/2, open-label, randomised trial. The Lancet. Infectious Diseases. 2025; 25: 25\u201335.","DOI":"10.1016\/S1473-3099(24)00493-6"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Fitz-Patrick D, McVinnie DS, Jackson LA, Crowther G, Geevarughese A, Cannon KD, et al. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine. The New England Journal of Medicine. 2025; 393: 2001\u20132011.","DOI":"10.1056\/NEJMoa2416779"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. The New England Journal of Medicine. 2025; 393: 2291\u20132302.","DOI":"10.1056\/NEJMoa2509907"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-S\u00e1nchez C, Loiacono MM, Harris RC, et al. Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis. Lancet (London, England). 2025; 406: 2425\u20132434.","DOI":"10.1016\/S0140-6736(25)01742-8"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, et al. High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical Trial. JAMA Cardiology. 2025; 10: 1186\u20131194.","DOI":"10.1001\/jamacardio.2025.3460"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet. Infectious Diseases. 2012; 12: 36\u201344.","DOI":"10.1016\/S1473-3099(11)70295-X"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Mirsaeidi M, Schraufnagel DE. Pneumococcal vaccines: understanding centers for disease control and prevention recommendations. Annals of the American Thoracic Society. 2014; 11: 980\u2013985.","DOI":"10.1513\/AnnalsATS.201401-042CME"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"A Heidenreich P, Bhatt A, Nazir NT, Schaffner W, Vardeny O. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Adult Immunizations as Part of Cardiovascular Care: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025; 86: 2085\u20132098.","DOI":"10.1016\/j.jacc.2025.07.003"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Garcia Quesada M, Peterson ME, Bennett JC, Hayford K, Zeger SL, Yang Y, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. The Lancet. Infectious Diseases. 2025; 25: 445\u2013456.","DOI":"10.1016\/S1473-3099(24)00588-7"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Huang L, Yang X, Li H, Xie Z, Zhu T, You W, et al. Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up. Human Vaccines & Immunotherapeutics. 2025; 21: 2517489.","DOI":"10.1080\/21645515.2025.2517489"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Barouch DH. Covid-19 Vaccines - Immunity, Variants, Boosters. The New England Journal of Medicine. 2022; 387: 1011\u20131020.","DOI":"10.1056\/NEJMra2206573"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet (London, England). 2020; 396: 1595\u20131606.","DOI":"10.1016\/S0140-6736(20)32137-1"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England Journal of Medicine. 2021; 384: 403\u2013416.","DOI":"10.1056\/NEJMoa2035389"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Winkelman TNA, Rai NK, Bodurtha PJ, Chamberlain AM, DeSilva M, Jeruzal J, et al. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021. JAMA Network Open. 2022; 5: e225018.","DOI":"10.1001\/jamanetworkopen.2022.5018"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Alves K, Kouassi A, Nelson J, Plested JS, Kalkeri R, Zhu M, et al. Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial. Vaccine. 2026; 73: 128164.","DOI":"10.1016\/j.vaccine.2025.128164"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Chalkias S, Dennis P, Petersen D, Radhakrishnan K, Vaughan L, Handforth R, et al. Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. The Lancet. Infectious Diseases. 2025; 25: 1230\u20131242.","DOI":"10.1016\/S1473-3099(25)00236-1"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Rout A, Suri S, Vorla M, Kalra DK. Myocarditis associated with COVID-19 and its vaccines - a systematic review. Progress in Cardiovascular Diseases. 2022; 74: 111\u2013121.","DOI":"10.1016\/j.pcad.2022.10.004"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Ohaeri C, Thomas DR, Salmon J, Cottrell S, Lyons J, Akbari A, et al. Comparative risk of cerebral venous sinus thrombosis (CVST) following COVID-19 vaccination or infection: A national cohort study using linked electronic health records. Human Vaccines & Immunotherapeutics. 2022; 18: 2127572.","DOI":"10.1080\/21645515.2022.2127572"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet (London, England). 2022; 399: 924\u2013944.","DOI":"10.1016\/S0140-6736(22)00152-0"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Havers FP, Whitaker M, Melgar M, Pham H, Chai SJ, Austin E, et al. Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023. JAMA Network Open. 2024; 7: e2444756.","DOI":"10.1001\/jamanetworkopen.2024.44756"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. The New England Journal of Medicine. 2023; 389: 2233\u20132244.","DOI":"10.1056\/NEJMoa2307079"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, et al. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025; 334: 1442\u20131451.","DOI":"10.1001\/jama.2025.15896"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, et al. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults. The New England Journal of Medicine. 2023; 388: 609\u2013620.","DOI":"10.1056\/NEJMoa2207566"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Mbinta JF, Wang AX, Nguyen BP, Paynter J, Awuni PMA, Pine R, et al. Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study. Nature Communications. 2023; 14: 4330.","DOI":"10.1038\/s41467-023-39595-y"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Tseng HF, Sy LS, Ackerson BK, Rayens E, Wu J, Luo Y, et al. Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults \u226550 Years in the United States. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2026; 81: e717\u2013e726.","DOI":"10.1093\/cid\/ciaf329"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Miller G, Schaefer H, Yoder S, Miller R, Winokur P, Kotloff K, et al. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. Transplant Infectious Disease. 2018; 20: e12874.","DOI":"10.1111\/tid.12874"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Nguyen TQ, Vlasenko D, Shetty AN, Zhao E, Reid CM, Clothier HJ, et al. Systematic review and meta-analysis of respiratory viral triggers for acute myocardial infarction and stroke. Cardiovascular Research. 2025; 121: 1330\u20131344.","DOI":"10.1093\/cvr\/cvaf092"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002; 105: 2143\u20132147.","DOI":"10.1161\/01.cir.0000016182.85461.f4"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013; 310: 1711\u20131720.","DOI":"10.1001\/jama.2013.279206"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Modin D, Lassen MCH, Claggett B, Johansen ND, Keshtkar-Jahromi M, Skaarup KG, et al. Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis. European Journal of Heart Failure. 2023; 25: 1685\u20131692.","DOI":"10.1002\/ejhf.2945"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Fr\u00f6bert O, G\u00f6tberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021; 144: 1476\u20131484.","DOI":"10.1161\/CIRCULATIONAHA.121.057042"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Jaiswal V, Ang SP, Lnu K, Ishak A, Pokhrel NB, Chia JE, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2022; 11: 3799.","DOI":"10.3390\/jcm11133799"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Hure A, Peel R, D'Este C, Abhayaratna WP, Tonkin A, Hopper I, et al. Prevention of Adverse Cardiovascular Events Using the 23-Valent Pneumococcal Polysaccharide Vaccine: A Randomized Clinical Trial. JAMA Cardiology. 2025; 10: 1112\u20131120.","DOI":"10.1001\/jamacardio.2025.3043"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Tong X, Gao L, Wong ICK, Chan VKY, Wong AYS, Mak JCW, et al. Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults: a population-based cohort study. International Journal of Epidemiology. 2024; 53: dyae005.","DOI":"10.1093\/ije\/dyae005"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, et al. Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial. JAMA. 2025; 334: 1431\u20131441.","DOI":"10.1001\/jama.2025.15405"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Pareek M, Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, et al. Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. European Heart Journal. 2025; 46: 4291\u20134298.","DOI":"10.1093\/eurheartj\/ehaf679"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Arunachalam S, Anuforo A, Hetelekides S, Olojakpoke E, Gupta N, Pichs Diez A, et al. Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched Analysis. Circulation. 2025; 152: A4366407.","DOI":"10.1161\/circ.152.suppl_3.4366407"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Helm MF, Khoury PA, Pakchanian H, Raiker R, Maczuga S, Foulke GT. Recombinant Zoster Vaccine Reduces 3-Year Cardiovascular Risk: Insights From a Multi-Centered Database. Journal of Drugs in Dermatology: JDD. 2023; 22: 1178\u20131182.","DOI":"10.36849\/JDD.7415"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Lee S, Lee K, Oh J, Kim HJ, Son Y, Kim S, et al. Live zoster vaccination and cardiovascular outcomes: a nationwide, South Korean study. European Heart Journal. 2025; 46: 2991\u20133002.","DOI":"10.1093\/eurheartj\/ehaf230"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Kornelius E, Lo SC, Huang CN, Wang CC, Wang YH, Yang YS. Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study. BMJ Open. 2025; 15: e090428.","DOI":"10.1136\/bmjopen-2024-090428"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Ip S, North TL, Torabi F, Li Y, Abbasizanjani H, Akbari A, et al. Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England. Nature Communications. 2024; 15: 6085.","DOI":"10.1038\/s41467-024-49634-x"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Xu Y, Li H, Santosa A, Wettermark B, Fall T, Bj\u00f6rk J, et al. Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study. European Heart Journal. 2025; 46: 147\u2013157.","DOI":"10.1093\/eurheartj\/ehae639"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Akbar UA, Thyagaturu H, Taha A, Atti L, Khan A, Raina S, et al. COVID-19 Vaccination and Cardiovascular Outcomes in Older Adults With Coronary Artery Disease and Heart Failure: Insights From a Large Propensity-Matched Cohort Study. Journal of the American Heart Association. 2025; 14: e044546.","DOI":"10.1161\/JAHA.125.044546"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Mercad\u00e9-Besora N, Li X, Kolde R, Trinh NT, Sanchez-Santos MT, Man WY, et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart (British Cardiac Society). 2024; 110: 635\u2013643.","DOI":"10.1136\/heartjnl-2023-323483"},{"key":"ref97","unstructured":"Garc\u00eda-Zamora S, Sosa Liprandi MI, Picco JM, Matta MG, Villarreal R, Pulido L, et al. Inmunizaciones en adultos con cardiopat\u00edas. Resumen del Consenso de la Sociedad Argentina de Cardiolog\u00eda [Immunizations in adults with cardiovascular disease. Summary of the Consensus of the Argentine Cardiology Society]. MEDICINA (Buenos Aires). 2020; 80: 541\u2013553."},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42: 3227\u20133337.","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022; 79: e263\u2013e421.","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148: e9\u2013e119.","DOI":"10.1161\/CIR.0000000000001168"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2024; 26: 5\u201317.","DOI":"10.1002\/ejhf.3024"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Heidecker B, Libby P, Vassiliou VS, Roubille F, Vardeny O, Hassager C, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement. European Heart Journal. 2025; 46: 3518\u20133531.","DOI":"10.1093\/eurheartj\/ehaf384"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Sedrak P, Dounaevskaia V, Mancini GBJ, Zieroth S, McKelvie RS, Chiu W, et al. Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review. CJC Open. 2025; 7: 1375\u20131388.","DOI":"10.1016\/j.cjco.2025.09.004"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"We\u0142nicki M, Kami\u0144ski K, Mastalerz-Migas A, Kuchar E, Jankowski P, Gil R, et al. Influenza vaccination as part of cardiovascular prevention - expert opinion supported by the Working Group on Cardiovascular Pharmacotherapy and Working Group on Prevention and Epidemiology Section of the Polish Cardiac Society. Kardiologia Polska. 2026; 84: 301\u2013308.","DOI":"10.33963\/v.phj.109619"},{"key":"ref106","unstructured":"Garcia-Zamora S, Pulido L, Sosa Liprandi MI, Nacinovich F, Balsano FJ, Herrera Paz JJ, et al. Consensus document on the role of adult vaccination in the prevention of cardiovascular events. Joint Statement by the Argentine Federation of Cardiology (FAC), Argentine Society of Cardiology (SAC), and the Argentine Council of Cardiology Residents (CONAREC). MEDICINA (Buenos Aires). 2026; 86: 447\u2013476."},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Achterbergh RCA, McGovern I, Haag M. Co-Administration of Influenza and COVID-19 Vaccines: Policy Review and Vaccination Coverage Trends in the European Union, UK, US, and Canada between 2019 and 2023. Vaccines. 2024; 12: 216.","DOI":"10.3390\/vaccines12020216"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM54010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:58:22Z","timestamp":1790693902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM54010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03942-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm54010","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"54010"}}